New executives to drive Life sciences and Fintech startups on the next journey

Following the closing of its oversubscribed CHF 103 million (USD 112 million) Series B round, Noema Pharma has welcomed Ilise Lombardo as the new CEO to advance its pipeline. She succeeded Luigi Costa, a co-founder of Noema, who has stepped down from the position after leading the company for three years to pursue other opportunities. Noema is a clinical-stage Biotech startup targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. It has a pipeline of four mid-clinical-stage therapeutic product candidates in-licensed from Roche, with three currently undergoing Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort and preclinical validation studies in Atypical Depression and Binge Eating Disorder.

Lombardo is a seasoned biopharma executive with more than 25 years of experience in the CNS space, spanning clinical practice, academic research, large pharma and biotech. She joined Noema Pharma’s Board of Directors in 2021 and will continue to serve on the Board. In 2019, she co-founded Arvelle Therapeutics, where she served as Chief Medical Officer. Furthermore, Lombardo was instrumental in building Arvelle into a launch-ready European CNS company, which was acquired by Angelini Pharma in 2021 for approximately $1 billion. Prior to joining Noema Pharma, Lombardo was President of the Therapeutics Division at gene therapy company Kriya Therapeutics. She has also held senior roles in clinical and medical development at Pfizer, Forum Pharmaceuticals and Axovant Sciences. She was previously on the faculty of Columbia University College of Physicians and Surgeons, and has completed two fellowships, one in neuroreceptor imaging and one in molecular genetics.

Amazentis welcomes Brian Ray to lead its rebranded company
Swiss Healthcare company Amazentis which is at the forefront of longevity research, has also appointed a new CEO after rebranding to Timeline.  Brian Ray, the former CEO of Garden of Life, which he co-founded in 2000 and later sold to Nestlé Health Science, will assume his new CEO role at Timeline. Garden of Life is one of the largest nutrition supplement brands in the United States, with revenues of approximately $1B a year and is the #1 selling brand in several categories at e-tailers such as Amazon.com and retail locations such as Whole Foods Market and Target. Garden of Life is also one of the most environmentally sustainable brands in the US and is Certified Carbon Neutral as well as B Corporation Certified. In his new role, he will lead Amazentis Timeline U.S. operations, enabling it to become the leading longevity consumer health brand in the United States and beyond.

The new name represents an important new chapter in the company's history, reinforcing the company's commitment to its mission of using cutting-edge health science to create a new consumer health category at the intersection of longevity, science and nutrition. The name Timeline represents the company’s dedication to enhancing the health span of individuals and positively influencing the healthy timeline of their lives.

Fintech startup Teylor welcomes new executives
Huy Nguyen and Andre Cordesmeyer have joined Zurich-based startup Teylor, assuming responsibility as Chief Financial Officer and Chief Commercial officer, respectively. The startup built the Teylor Credit Platform, a suite of software modules that enable financial institutions to build, deliver and scale digital credit products. Over the past three years, Teylor has processed more than €3 billion in financing requests. More than a dozen European banks and financial service providers already use Teylor's Software-as-a-Service solutions to digitise the loan lifecycle.

Huy Nguyen joined Teylor in 2021. Previously, he executed leveraged and structured finance transactions in the DACH region at Deutsche Bank. When joining Teylor, Huy Nguyen was initially responsible for the business of Teylor Capital as Head of Private Debt, managing deal execution, portfolio management and capital raising. In this role, he arranged the largest self-arranged fundraising of the year to date in the fintech and alternative direct lending industry in the private debt market. Huy Nguyen will continue in this role, leading the Teylor Capital team and additionally supporting the company's strategic development as CFO.

Andre Cordesmeyer joined Teylor in 2019, shortly after the company was founded. He previously worked as regional sales manager for Ulm-based industrial group Liqui Moly in the UK. At Teylor, he took the role of Head of Sales and was responsible for establishing and expanding the origination efforts of the Teylor platform. Since Teylors foundation, his team has executed over €300 million in financing volume. As CCO, Andre Cordesmeyer will build on this success and lead the expansion of the company’s lending origination and partner network in Europe.

(Press release/RAN)